Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 20, 2024 - Issue 1
Submit an article Journal homepage
1,532
Views
0
CrossRef citations to date
0
Altmetric
Coronavirus

Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab

Tjalf Ziemssena Department of Neurology, Center of Clinical Neuroscience, Carl Gustav Carus University Clinic, University Hospital of Dresden, Technische Universität Dresden, Dresden, GermanyCorrespondence[email protected]
View further author information
,
Marie Grothb Medical Franchise Neuroscience, Novartis Pharma GmbH, Nuremberg, GermanyView further author information
,
Benjamin Ettleb Medical Franchise Neuroscience, Novartis Pharma GmbH, Nuremberg, GermanyView further author information
&
Tobias Boppc Institute for Immunology, University Medical Center of the Johannes Gutenberg University, Mainz, GermanyView further author information
Article: 2316422 | Received 14 Dec 2023, Accepted 06 Feb 2024, Published online: 12 Feb 2024

References

  • Robert Koch-Institut. Stellungnahme der STIKO anlässlich der Zulassung von XBB.1.5-Varianten-adaptierten COVID-19-Impfstoffen für die Auffrischimpfung von Personen mit erhöhtem Risiko für einen schweren Krankheits­verlauf; 2023. https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Stellungnahme-COVID-19-Varianten-adaptierte-Impfstoffe.html.
  • World Health Organization. COVID-19 advice for the public: getting vaccinated; 2023. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice.
  • Ziemssen T, Schlegel E, Groth M, Ettle B, Bopp T. Results on SARS-CoV-2 mRNA vaccine booster from an open-label multicenter study in ofatumumab-treated participants with relapsing multiple sclerosis. Vaccines (Basel). 2023;11(5):11. doi:10.3390/vaccines11050978.
  • Ziemssen T, Groth M, Ettle B, Bopp T. Immune response to SARS-CoV-2 mRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with Ofatumumab. Vaccines (Basel). 2022;10(12):2167. doi:10.3390/vaccines10122167.
  • He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Kubala Havrdova E, Spelman T, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307–4. doi:10.1016/S1474-4422(20)30067-3.
  • Koeditz D, Frensch J, Bierbaum M, Ness N-H, Ettle B, Vudumula U, Gudala K, Adlard N, Tiwari S, Ziemssen T. Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: a cost-consequence analysis from a societal perspective in Germany. Mult Scler J Exp Transl Clin. 2022;8(1):20552173221085741. doi:10.1177/20552173221085741.
  • Carrillo J, Izquierdo-Useros N, Avila-Nieto C, Pradenas E, Clotet B, Blanco J. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem Biophys Res Commun. 2021;538:187–91. doi:10.1016/j.bbrc.2020.10.108.
  • Arunachalam PS, Lai L, Samaha H, Feng Y, Hu M, Hui HSY, Wali B, Ellis M, Davis-Gardner ME, Huerta C, et al. Durability of immune responses to mRNA booster vaccination against COVID-19. J Clin Invest. 2023;133(10):133. doi:10.1172/jci167955.
  • Ziemssen T, Groth M, Winkelmann VE, Bopp T. Immune response to initial and booster SARS-CoV-2 mRNA vaccination in patients treated with siponimod—final analysis of a nonrandomized controlled clinical trial (AMA-VACC). Vaccines (Basel). 2023;11(8):11. doi:10.3390/vaccines11081374.
  • Otto C, Schwarz T, Jeworowski LM, Schmidt ML, Walper F, Pache F, Schindler P, Niederschweiberer M, Krumbholz A, Rose R, et al. Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations. Mult Scler. 2023;29(7):884–888. doi:10.1177/13524585231161253.
  • Woopen C, Dunsche M, Al Rahbani GK, Dillenseger A, Atta Y, Haase R, Raposo C, Pedotti R, Ziemssen T, Akgün K, et al. Long-term immune response profiles to SARS-CoV-2 vaccination and infection in people with multiple sclerosis on anti-CD20 therapy. Vaccines (Basel). 2023;11(9):11. doi:10.3390/vaccines11091464.
  • Schiavetti I, Inglese M, Frau J, Signoriello E, Caleri F, Stromillo ML, Ferrò MT, Rilla MT, Gandoglia I, Gazzola P, et al. Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: who gains from it? Eur J Neurol. 2023;30(8):2357–2364. doi:10.1111/ene.15830.
  • Haase S, Krickl A-L, Freudenstein D, Burner F, Angstwurm K, Lee DH, Linker R. Subcutaneous anti-CD20 targeted B cell depletion preserves memory B cells and IgG serum levels in patients with RRMS (P280/442). Mult Scler J. 2023;29. doi:10.1177/13524585231196192.
  • Cross AH, Delgado S, Habek M, Davydovskaya M, Ward BJ, Cree BAC, Totolyan N, Pingili R, Mancione L, Hu X, et al. COVID-19 outcomes and vaccination in people with relapsing multiple sclerosis treated with ofatumumab. Neurol Ther. 2022;11(2):741–758. doi:10.1007/s40120-022-00341-z.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.